Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947552616> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2947552616 abstract "e15007 Background: Afl is one of the antiagiogenic agents used for the treatment for mCRC. Cardiovascular toxicity of Afl is shown to be a main reason of the drug discontinuation but there are no studies on factors associated with nonhem adverse events(AEs). The aim of the study was to define clinical factors associated with the development of Gd.3-4 nonhem AEs. Methods: Pts with mCRC treated with FOLFIRI+Afl were included in a multicenter prospective base from 2016-18. Multivariative regression analysis was performed with Chicago, IL v.22.0. Factors studied included demographic, disease characteristics, data about concomitant diseases(CD) and concomitant medications. Results: 278 pts with mCRC from 18 centers were included. Mean age – 58.7, 48.6% were male, mean number of metastases– 2. ECOG 0-1–97.5%pts. RASm had 133 (47.8%) pts. Afl+FOLFIRI was used as the 2nd line therapy–in 67.6%. CD were in 194 (69.8%), cardiovascular–in 175 (62.9%). ORR(CR+PR)17.3%, SD-43.9%. MedPFS was 6.0 mos. Afl discontinuation due to AEs 11.9%. AE were reported in 201 (72.3%), Gd3-4 – in 69 (24.8%); nonhem AEs – in 178 (64%), Gd3-4–52 (18.8%)pts. Among Gd3-4 nonhem AEs were arterial hypertension Gd1-2–77 (27.7%), Gd3-4-in 36 (12.9%), vomiting Gd1-2–45 (16.2%), diarrhea Gd1-2–in 32 (11.5%), asthenia Gd1-2 –in 29 (10.4%), hepatotoxicity Gd1-2–in 2(5%), thrombosis–in 2 (5%) pts. Multivariate regression analysis showed that among the factors studied number of lines of treatment (OR1.4,95%CI1.1-2.1,p=0.03) and CD requiring medical support (OR 2.0,95%CI1.1-3.7,p=0.03) were found as independent factors of nonhem AE Gd3-4 development. ACE-inhibitors (OR2.2,95%CI1.2-4.3,p=0.02), calcium-channel blockers (CCB)(OR4.1,95%CI1.6-10.4,p=0.003 ) were the medical drugs considered to be significant. Conclusions: Number of lines and CD requiring medical support, especially with ACE-inhibitors or CCB, identifies a significant risk of developing cardiovascular non-hem AEs Gd3-4 with FOLFIRI + Afl." @default.
- W2947552616 created "2019-06-07" @default.
- W2947552616 creator A5000844601 @default.
- W2947552616 creator A5007815463 @default.
- W2947552616 creator A5011307838 @default.
- W2947552616 creator A5012700479 @default.
- W2947552616 creator A5016431282 @default.
- W2947552616 creator A5019534168 @default.
- W2947552616 creator A5025269387 @default.
- W2947552616 creator A5026725606 @default.
- W2947552616 creator A5027929583 @default.
- W2947552616 creator A5031362509 @default.
- W2947552616 creator A5036692508 @default.
- W2947552616 creator A5052477878 @default.
- W2947552616 creator A5056705823 @default.
- W2947552616 creator A5062535720 @default.
- W2947552616 creator A5063181948 @default.
- W2947552616 creator A5068004550 @default.
- W2947552616 creator A5077389402 @default.
- W2947552616 creator A5077639518 @default.
- W2947552616 creator A5080856237 @default.
- W2947552616 creator A5087160559 @default.
- W2947552616 date "2019-05-20" @default.
- W2947552616 modified "2023-10-01" @default.
- W2947552616 title "Aflibercept (Afl) for patients (pts) with metastatic colorectal cancer (mCRC): Clinical predictors of nonhematologic (nonhem) toxicity." @default.
- W2947552616 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e15007" @default.
- W2947552616 hasPublicationYear "2019" @default.
- W2947552616 type Work @default.
- W2947552616 sameAs 2947552616 @default.
- W2947552616 citedByCount "0" @default.
- W2947552616 crossrefType "journal-article" @default.
- W2947552616 hasAuthorship W2947552616A5000844601 @default.
- W2947552616 hasAuthorship W2947552616A5007815463 @default.
- W2947552616 hasAuthorship W2947552616A5011307838 @default.
- W2947552616 hasAuthorship W2947552616A5012700479 @default.
- W2947552616 hasAuthorship W2947552616A5016431282 @default.
- W2947552616 hasAuthorship W2947552616A5019534168 @default.
- W2947552616 hasAuthorship W2947552616A5025269387 @default.
- W2947552616 hasAuthorship W2947552616A5026725606 @default.
- W2947552616 hasAuthorship W2947552616A5027929583 @default.
- W2947552616 hasAuthorship W2947552616A5031362509 @default.
- W2947552616 hasAuthorship W2947552616A5036692508 @default.
- W2947552616 hasAuthorship W2947552616A5052477878 @default.
- W2947552616 hasAuthorship W2947552616A5056705823 @default.
- W2947552616 hasAuthorship W2947552616A5062535720 @default.
- W2947552616 hasAuthorship W2947552616A5063181948 @default.
- W2947552616 hasAuthorship W2947552616A5068004550 @default.
- W2947552616 hasAuthorship W2947552616A5077389402 @default.
- W2947552616 hasAuthorship W2947552616A5077639518 @default.
- W2947552616 hasAuthorship W2947552616A5080856237 @default.
- W2947552616 hasAuthorship W2947552616A5087160559 @default.
- W2947552616 hasConcept C121608353 @default.
- W2947552616 hasConcept C126322002 @default.
- W2947552616 hasConcept C143998085 @default.
- W2947552616 hasConcept C2776694085 @default.
- W2947552616 hasConcept C2777802072 @default.
- W2947552616 hasConcept C2778715236 @default.
- W2947552616 hasConcept C2778749236 @default.
- W2947552616 hasConcept C29730261 @default.
- W2947552616 hasConcept C526805850 @default.
- W2947552616 hasConcept C71924100 @default.
- W2947552616 hasConceptScore W2947552616C121608353 @default.
- W2947552616 hasConceptScore W2947552616C126322002 @default.
- W2947552616 hasConceptScore W2947552616C143998085 @default.
- W2947552616 hasConceptScore W2947552616C2776694085 @default.
- W2947552616 hasConceptScore W2947552616C2777802072 @default.
- W2947552616 hasConceptScore W2947552616C2778715236 @default.
- W2947552616 hasConceptScore W2947552616C2778749236 @default.
- W2947552616 hasConceptScore W2947552616C29730261 @default.
- W2947552616 hasConceptScore W2947552616C526805850 @default.
- W2947552616 hasConceptScore W2947552616C71924100 @default.
- W2947552616 hasLocation W29475526161 @default.
- W2947552616 hasOpenAccess W2947552616 @default.
- W2947552616 hasPrimaryLocation W29475526161 @default.
- W2947552616 hasRelatedWork W2240209967 @default.
- W2947552616 hasRelatedWork W2240838598 @default.
- W2947552616 hasRelatedWork W2324888499 @default.
- W2947552616 hasRelatedWork W2410958286 @default.
- W2947552616 hasRelatedWork W2546154929 @default.
- W2947552616 hasRelatedWork W2588552646 @default.
- W2947552616 hasRelatedWork W2590116100 @default.
- W2947552616 hasRelatedWork W2590377359 @default.
- W2947552616 hasRelatedWork W2592898585 @default.
- W2947552616 hasRelatedWork W2898221561 @default.
- W2947552616 hasRelatedWork W3004966300 @default.
- W2947552616 hasRelatedWork W3012415429 @default.
- W2947552616 hasRelatedWork W3029741075 @default.
- W2947552616 hasRelatedWork W3031352853 @default.
- W2947552616 hasRelatedWork W3047135805 @default.
- W2947552616 hasRelatedWork W3095986263 @default.
- W2947552616 hasRelatedWork W3136733183 @default.
- W2947552616 hasRelatedWork W3166456074 @default.
- W2947552616 hasRelatedWork W3195895258 @default.
- W2947552616 hasRelatedWork W2909787771 @default.
- W2947552616 isParatext "false" @default.
- W2947552616 isRetracted "false" @default.
- W2947552616 magId "2947552616" @default.
- W2947552616 workType "article" @default.